{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"4.7","upperLimit":"19.1","value":"8.4"}]}],"title":"Independent radiologist assessed, n=0, 11"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"11.7","value":"8.1"}]}],"title":"Investigator assessed, n=0, 23"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Time to response was defined as the time from the date of randomization until the date of first documented evidence of CR or PR (whichever status was recorded first). The Kaplan-Meier method was used for time to response estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG000","title":"Placebo"},{"description":"Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG001","title":"Pazopanib"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only participants who achieved a confirmed CR or PR, as determined independently by the Independent Radiologist and the Investigator, were analyzed. Only results for the pazopanib arm are given because there was no response in the placebo arm.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until the date of the first documented evidence of CR or PR (assessed for an average of 10 months)","title":"Time to Response Assessed by an Independent Radiologist and the Investigator","type":"SECONDARY","unitOfMeasure":"weeks"}